Savara shuts down another cystic fibrosis program after a PhIII flop, as it prepares to axe staff and re-center around aPAP
2020 hasn’t been a good year for Savara Pharmaceuticals, and the hits kept coming as another trial in cystic fibrosis flopped Friday.
The Austin, TX …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
